-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, follow-up analysis data from the first phase III clinical trial of the divalent HPV vaccine Cecolin (Cecone) were published
In terms of safety, the incidence of serious adverse events was similar in the vaccination and control groups, and both were not related to
vaccination.
In December 2019, Wantai Canghai's bivalent human papillomavirus vaccine (E.
coli) (trade name: Xinkoning) was approved by the Food and Drug Administration for use in women aged 9-45, becoming the first domestic HPV vaccine
approved.
At present, there are 5 HPV vaccines on the market in China, namely Merck's 4-valent and 9-valent vaccines (Zhifei Biological Agent), GSK's 2-valent vaccine, and Wantai Bio's 2-valent vaccine (trade name: Xinkenin) and Watson Bio's 2-valent HPV vaccine
.
It is reported that in 2020, the sales volume of Xinkoning in China is about RMB693 million
.
